Loading
Life sciences · Journal article
Acs Nano · November 5, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Bladder cancer is a type of prevalent malignant tumor of the urinary system, for which transurethral endoscopic resection serves as the first-line clinical treatment, followed by adjuvant intravesical chemotherapy or BCG immunotherapy. Current clinical regimens suffer largely from surgical trauma, procedural risks, long treatment cycles, severe systemic side effects, and high recurrence rates; conventional tumor cell-killing modalities relying on highly toxic chemotherapeutics and vaccines will inevitably damage normal tissues and induce less-tolerable adverse reactions in patients. By overturning this conventional therapeutic philosophy, we previously proposed a globally pioneering bladder cancer disaggregation therapy: calcium chelation disrupts intercellular cadherin-mediated adhesion, triggering exfoliation and detachment of tumor cells, which are subsequently excreted from the body via urine. Taking advantage of the unique anatomical and physiological characteristics of the bladder, this strategy achieves noninvasive tumor elimination through spontaneous urinary expulsion. To further enhance the disaggregation efficiency, the present work advances this concept by incorporating collagenase to realize the dual disruption of both cadherin and collagen proteins. To this end, we constructed a layered double hydroxide (LDH) nanoplatform coloaded with collagenase and EDTA. The nanosystem efficiently degrades key extracellular matrix components, thereby relieving steric hindrance and exposing cellular surfaces, which significantly promotes the subsequent disruption of intercellular junctions via enhanced EDTA accessibility for calcium deprivation from E-cadherin. This work establishes an efficient, noncell-killing modality for the physical clearance of bladder tumors, offering a promising alternative clinical strategy to suppress tumor recurrence and reduce systemic toxic side effects.